Keywords: Pfizer, Biocon, Insulin, Biosimilars, Emerging markets, Follow-on biologicals

Pfizer buys rights to insulin biosimilars in $350 million deal with India’s Biocon

Article | 19 October 2010

Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an agreement with global drugs behemoth Pfizer (NYSE: PFE) for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Biocon

Pfizer

Go to company listing